Nonsurgical treatment of recurrent glioblastoma

Current Oncology

Volumn 22, Issue 4, 2015, Pages e273-e281

  Gallego, O ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Chemotherapy; Glioblastoma; Recurrent disease

Indexed keywords

EID: 84939638314     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2436     Document Type: Review

References (69)

1. Central Brain Tumor Registry of the United States (cbtrus). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2007. Hinsdale, IL: cbtrus; 2011. [Available online at: http://www. cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011. pdf; cited 28 June 2012]
2. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Ver. n.s. Fort Washington, PA: nccn; 2014. [Current version available online at: http://www.nccn.org/ professionals/physician_gls/pdf/cns.pdf (free registration required); cited 1 June 2015]
3. Little MP, Rajaraman P, Curtis RE, et al. MS Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States. BMJ 2012;344:e1147.
4. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro Oncol 2013;15:4–27.
5. Stupp R, Mason WP, van den Bent MJ, et al. on behalf of the eortc Brain Tumor and Radiotherapy Groups, and the ncic Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
6. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.
7. Wick W, Platten M, Meisner C, et al. on behalf of the noa-08 Study Group of the Neuro-Oncology Working Group (noa) of the German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the noa-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707–15.
8. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709–22.
9. Gilbert MR, Dignam J, Won M, et al. rtog 0825: phase iii double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (gbm) [abstract 01]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary.asco.org/content/111571-132; cited 18 May 2015]
10. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72.
11. Barker FG 2nd, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998;42:709–20.
12. Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 2010;28:3838–43.
13. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer–Brain Tumor Treatment Group. Lancet 1995;345:1008–12.
14. Torok JA, Wegner RE, Mintz AH, Heron DE, Burton SA. Reirradiation with radiosurgery for recurrent glioblastoma multiforme. Technol Cancer Res Treat 2011;10:253–8.
15. Yung WK, Albright RE, Olson J, et al. A phase ii study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588–93.
16. Happold C, Roth P, Wick W, et al. acnu-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 2009;92:45–8.
17. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase ii trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: eortc Brain Tumor Group Study 26034. J Clin Oncol 2009;27:1268–74.
18. Brandes AA, Tosoni A, Amistà P, et al. How effective is bcnu in recurrent glioblastoma in the modern era? A phase ii trial. Neurology 2004;63:1281–4.
19. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G. bcnu for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer 2010;10:30.
20. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase iii study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28:1168–74.
21. Addeo R, Caraglia M, De Santi MS, et al. A new schedule of fotemustina in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol 2011;102:417–24. [Erratum in: J Neurooncol 2011;102:425]
22. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase ii trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259–66.
23. Brandes AA, Ermani M, Basso U, et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase ii study. Ann Oncol 2001;12:255–7.
24. Brandes AA, Ermani M, Basso U, et al. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea–procarbazine failure: a phase ii study. Oncology 2002;63:38–41.
25. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase ii study from Gruppo Italiano Cooperativo di Neuro-Oncologia (gicno). Br J Cancer 2006;95:1155–60.
26. Balmaceda C, Peereboom D, Pannullo S, et al. Multiinstitutional phase ii study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 2008;112:1139–46.
27. Berrocal A, Perez Segura P, Gil M, et al. on behalf of the genom Cooperative Group. Extended-schedule dose dense temozolomide in refractory gliomas. J Neurooncol 2010;96:417–22.
28. Perry JR, Bélanger K, Mason WP, et al. Phase ii trial of continuous dose intense temozolomide in recurrent malignant glioma: rescue study. J Clin Oncol 2010;28:2051–7.
29. Hammond A, Norden AD, Lesser GJ, et al. Phase ii study of dose intense temozolomide in recurrent glioblastoma [abstract 2038]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary.asco.org/content/73944-102; cited 18 May 2015]
30. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007;25:3357–61.
31. Yung WK, Albright RE, Olson J, et al. A phase ii study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588–93.
32. Weller M, Tabatabai G, Reifenberger G, et al. Dose-intensified rechallenge with temozolomide: one week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma [abstract TPS154]. J Clin Oncol 2010;28:. [Available online at: http://meeting.ascopubs.org/ cgi/content/abstract/28/15_suppl/TPS154; cited 18 May 2015]
33. Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M. pcv chemotherapy for recurrent glioblastoma. Neurology 2006;66:587–9.
34. Batchelor TT, Mulholland P, Neyns B, et al. Phase iii randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31:3212–18.
35. Gaviani P, Salmaggi A, Silvani A. Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients. J Neurooncol 2011;104:617–18.
36. Zustovich F, Landi L, Lombardi G, et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase ii study. Anticancer Res 2013;33:3487–94.
37. Stockhammer F, Misch M, Koch A, et al. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol 2010;100:407–15.
38. 6 -benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 2009;27:1262–7.
39. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733–40.
40. Kreisl TN, Kim L, Moore K, et al. Phase ii trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740–5.
41. Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010;116:5297–305.
42. Chamberlain MC, Johnston SK. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 2010;96:259–69.
43. Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. J Clin Neurosci 2012;19:1636–40.
44. Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase ii trial. Neuro Oncol 2010;12:508–16.
45. Francesconi AB, Dupre S, Matos M, et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci 2010;17:970–4.
46. Reardon DA, Desjardins A, Peters KB, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011;117:5351–8.
47. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase ii trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 2010;12:1300–10.
48. Taal W, Oosterkamp HM, Walenkamp AME, et al. A randomized phase ii study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch belob study [abstract 2001]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary. asco.org/content/109069-132; cited 18 May 2015]
49. Brandes A, Fichocchiaro G, Zagonel V, et al. Randomized phase ii trial avareg (ML25739) with bevacizumab (bev) or fotemustine (ftm) in recurrent gbm: final results from the randomized phase ii trial. Ann Oncol 2014;25(suppl 4):iv137–45.
50. de Groot JF, Lamborn KR, Chang SM, et al. Phase ii study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2011;29:2689–95.
51. Wen PY, Prados M, Schiff D, et al. Phase ii study of XL184 (BMS 907351), an inhibitor of met, vegfr2, and ret, in patients (pts) with progressive glioblastoma (gb) [abstract 2006]. J Clin Oncol 2010;28:. [Available online at: http://meetinglibrary. asco.org/content/44555-74; cited 18 May 2015]
52. Rich JN, Reardon DA, Peery T, et al. Phase ii trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133–42.
53. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastoma to egfr kinase inhibitors. N Engl J Med 2005;353:2012–24.
54. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880–7.
55. Gallego O, Cuatrecasas M, Benavides M, et al. Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed egfrviii and pten determined by immunohistochemistry. J Neurooncol 2014;116:413–19.
56. Yung WK, Vredenburgh JJ, Cloughesy TF, et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase ii open-label study. Neuro Oncol 2010;12:1061–70.
57. Raizer JJ, Abrey LE, Lassman AB, et al. on behalf of the North American Brain Tumor Consortium. A phase ii trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. J Neuro Oncol 2010;12:95–103.
58. Nguyen TD, Lassman AB, Lis E, et al. A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (gbm) [abstract 1507]. J Clin Oncol 2006;24:. [Available online at: http://meeting.ascopubs.org/cgi/content/short/24/18_ suppl/1507; cited 19 May 2015]
59. Doherty L, Gigas DC, Kesari S, et al. Pilot study of the combination of egfr and mtor inhibitors in recurrent malignant gliomas. Neurology 2006;67:156–8.
60. de Groot JF, Gilbert MR, Aldape K, et al. Phase ii study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 2008;90:89–97.
61. Eisenstat DD, Nabors LB, Mason WP, et al. A phase ii study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma [abstract 2010]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary.asco.org/content/80065-102; cited 19 May 2015]
62. Schaiquevich P, Panetta JC, Throm S, et al. Pharmacokinetic analysis of erlotinib and OSI-420 in pediatric patients with malignant gliomas [abstract]. Nature 2008;83:S51.
63. Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012;70:399–405.
64. Vivanco I, Robins HI, Rohle D, et al. Differential sensitivity of glioma- versus lung cancer–specific EGFR mutations to egfr kinase inhibitors. Cancer Discov 2012;2:458–71.
65. Mohme M, Neidert MC, Regli L, Weller M, Martin R. Immunological challenges for peptide-based immunotherapy in glioblastoma. Cancer Treat Rev 2014;40:248–58.
66. Bregy A, Wong TM, Shah AH, Goldberg JM, Komotar RJ. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev 2013;39:891–907.
67. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase ii study of cilengitide, an integrin-targeting arginine–glycine– aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610–17.
68. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase iii trial of a novel treatment modality. Eur J Cancer 2012;48:2192–202.
69. Stupp R, Wong E, Scott C, et al. Interim analysis of the ef 14 trial: a prospective, multicenter trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed gbm. Neuro Oncol 2014;16(suppl 5):167.